Oclacitinib is a non-selective JAK inhibitor (JAK1 and JAK3 inhibitor) compound that suppresses proinflammatory cytokines associated with canine AD pathobiology including IL-2, IL-4, IL-6, IL-13, and IL-31 [7, 8] and was approved for use in dogs by the U.S. Food and Drug Administration, Center of Veterinary Medicine in 2013. The gene discussed is JAK1; the disease is Alzheimer disease.